Evidence map›Paper›PMID 42307760›Full record

ArticleJournal of bone and mineral metabolism2026

24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore.

Tang Ching Lau, Dong-Gune Chang, Chung-Hwan Chen, Shuang Huang, Edith M C Lau, Sheung-Wai Law, Young-Kyun Lee, Cae Tolman, Laura Canals, See-Hwee Yeo and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tang Ching LauDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Dong-Gune ChangDepartment of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, South Korea.
Chung-Hwan ChenDepartment of Orthopedics and Orthopedic Research Center, Kaohsiung Medical University Hospital, College of Medicine, Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Shuang HuangAmgen Inc., Thousand Oaks, CA, USA.
Edith M C LauHong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China.
Sheung-Wai LawDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.
Young-Kyun LeeSeoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Cae TolmanAmgen Australia, Sydney, Australia.
Laura CanalsDepartment of Medicine, Amgen Europe, Amgen GmbH, Suurstoffi 22, 6343, Rotkreuz, Switzerland. lcanals@amgen.com.
See-Hwee YeoReal World Solutions, IQVIA Solutions Asia, Singapore, Singapore.
Peter R EbelingDepartment of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo compare 24-month persistence and compliance of denosumab with alendronate in postmenopausal women with osteoporosis across 5 Asia-Pacific territories. MATERIALS AND

methodsThis prospective cohort study included women aged ≥ 50 years from Australia, Taiwan, South Korea, Hong Kong, and Singapore. Participants received either a bi-annual denosumab injection or weekly oral alendronate as osteoporosis treatment, based on physician judgment. Multivariable logistic regression assessed whether therapy (denosumab or alendronate) was significantly associated with treatment persistence and compliance over 24 months of follow-up. The models were adjusted for age, fracture history, baseline bone mineral density (BMD), prior osteoporosis therapy, and prior oral glucocorticoid treatment. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated.

resultsAmong 687 enrolled patients, 549 completed their 24-month visit (295 in denosumab and 254 in alendronate group). Patients in the denosumab group were older and a higher proportion previously received osteoporosis treatment. Overall treatment persistence and compliance were 74.9% and 56.6%, respectively. Patients prescribed with denosumab exhibited higher persistence (86.1% vs. 61.8%; P < 0.001) and compliance (62.4% vs. 50.0%; P = 0.004), compared with those on alendronate. Regression results also demonstrated that patients receiving denosumab were more likely to be persistent (aOR = 3.91; 95% CI 2.52-6.08), and compliant (aOR = 1.61; 95% CI 1.12-2.31). BMD T-scores improved in both the treatment groups after 24 months with no significant association between treatment type and change in T-score. No significant difference was also observed in the occurrence of adverse events between the two treatment cohorts. Patients on alendronate reported gastrointestinal issues more frequently, whereas those on denosumab had a higher incidence of bone and joint injuries.

conclusionPostmenopausal women with osteoporosis were more likely to be persistent and compliant with a bi-annual denosumab injection, compared with weekly oral alendronate.

Indexed as

AlendronateDenosumabMedication complianceMedication persistenceOsteoporosis

Identifiers

PMID42307760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.